Jacobs Levy Equity Management
AERI

Jacobs Levy Equity Management’s Aerie Pharmaceuticals AERI Stock Holding History

Jacobs Levy Equity Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-200,808
Closed -$3.04M – 1082
2022
Q3 		$3.04M Sell
200,808
-982,868
-83% -$11.4M 0.02% 478
2022
Q2 		$8.88M Buy
1,183,676
+92,379
+8% +$651K 0.07% 301
2022
Q1 		$9.93M Buy
1,091,297
+76,741
+8% +$592K 0.07% 297
2021
Q4 		$7.12M Buy
1,014,556
+409,917
+68% +$4.29M 0.05% 362
2021
Q3 		$6.89M Buy
604,639
+26,807
+5% +$392K 0.05% 369
2021
Q2 		$9.25M Buy
577,832
+377,604
+189% +$6.48M 0.06% 313
2021
Q1 		$3.58M Sell
200,228
-341,947
-63% -$5.91M 0.03% 493
2020
Q4 		$7.33M Buy
542,175
+391,385
+260% +$4.73M 0.06% 321
2020
Q3 		$1.77M Buy
+150,790
New +$1.84M 0.02% 540

Jacobs Levy Equity Management's AERI Position: Q4 2022 in Review

Jacobs Levy Equity Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 200,808 shares — an estimated $3.04M sold.

Jacobs Levy Equity Management first reported a position in AERI in Q3 2020 and held it in 9 quarters. The position peaked at $9.93M in Q1 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

  • Jacobs Levy Equity Management reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 200,808 Aerie Pharmaceuticals shares in Q4 2022, an estimated $3.04M.
  • Jacobs Levy Equity Management first reported a position in Aerie Pharmaceuticals in Q3 2020 and held it in 9 quarters.
  • Jacobs Levy Equity Management's Aerie Pharmaceuticals position peaked at $9.93M in Q1 2022.
  • 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2022, filed 14 Feb 2023.